Interleukin 20 (IL-20) and its use in neovascularisation
AssigneeNovo Nordisk A/S
InventorsUffe Olsen, Anker Hansen, John Romer, Erik Hasselager, Jes Clausen, Lars Iversen
Life of this patent
Estimating the term…
Abstract
The invention provides a novel method of regulating neovascularisation.
Claims5
A pharmaceutical composition comprising IL-20 or an analogue, active fragment or derivative thereof, together with pharmaceutically acceptable carriers or diluents.
A pharmaceutical composition comprising an antagonist of IL-20 or an analogue, active fragment or derivative thereof, together with pharmaceutically acceptable carriers or diluents
A method of promoting neovascularisation, said method comprising administering to a mammal in need thereof an effective amount of IL-20 or an analogue, active fragment or derivative thereof.
A method of inhibiting neovascularisation said method comprising administering to a mammal in need thereof an effective amount of an antagonist of IL-20 or an analogue, active fragment or derivative thereof.
A method of diagnosing a state of disease involving neovascularisation in a mammal, said method comprising analysing IL-20 activity of said mammal.
Dependencies are inferred from the claim text.